Opticyte, Inc.
Opticyte is a medical device company dedicated to transforming the standard of care for hemorrhage, sepsis, and other leading causes of organ failure. Their mission is to save lives through early detection and real-time measurement of cellular and blood oxygen levels, providing accurate diagnostics for all skin tones and addressing critical health equity issues. Founded in 2016 as a spinout from the University of Washington, Opticyte is pioneering the first device to measure oxygen inside cells in real time, aiming to reduce organ failure and death associated with hemorrhage, sepsis, and other critical illnesses. The company is recognized for its innovative approach, commitment to health equity, and strong leadership in medical technology.
Industries
Nr. of Employees
small (1-50)
Opticyte, Inc.
4000 Mason Road, Suite 300 Seattle, WA 98195
Opticyte, Inc. is currently seeking investment
Opticyte, Inc. is seeking a seed investment in the range of less-than-1m
Products
Noninvasive cellular O2 patient monitor (bedside/clinical monitor)
A bedside patient monitor that noninvasively measures and displays real-time oxygen levels inside cells using optical spectroscopy and algorithmic interpretation to aid early detection of organ dysfunction.
Noninvasive cellular O2 patient monitor (bedside/clinical monitor)
A bedside patient monitor that noninvasively measures and displays real-time oxygen levels inside cells using optical spectroscopy and algorithmic interpretation to aid early detection of organ dysfunction.
Expertise Areas
- Clinical trial design and hospital-based observational studies
- Optical spectroscopy and noninvasive oximetry development
- Machine learning for biosignal analysis and fairness-aware model training
- Regulatory strategy and expedited FDA pathways
Key Technologies
- Optical spectroscopy for tissue and cellular oxygenation
- Noninvasive cellular oximetry
- Machine learning for biosignal interpretation
- Real-time continuous physiological monitoring
Key People
News & Updates
The Opticyte VitalO₂ received Breakthrough Device Designation from the US FDA for its potential to provide more effective treatment over the existing standard of care for identifying and treating life-threatening organ dysfunction.
Recognized by Inc. Media Magazine as a top 10 medical device innovator in 2025.
Opticyte was selected as a finalist for the MedTech Innovator Award in 2023.
Opticyte was selected for the MedTech Accelerator 2023 cohort, recognizing its innovation and growth potential.
Opticyte was featured in Inc. Media Magazine as a top 10 medical device innovator.
Opticyte's technology and mission were highlighted in an NIH article.
The Opticyte VitalO₂ received Breakthrough Device Designation from the US FDA for its potential to provide more effective treatment over the existing standard of care for identifying and treating life-threatening organ dysfunction.
Recognized by Inc. Media Magazine as a top 10 medical device innovator in 2025.
Opticyte was selected as a finalist for the MedTech Innovator Award in 2023.
Opticyte was selected for the MedTech Accelerator 2023 cohort, recognizing its innovation and growth potential.
Opticyte was featured in Inc. Media Magazine as a top 10 medical device innovator.
Opticyte's technology and mission were highlighted in an NIH article.